IntelGenx Corp. Grants Stock Options

SAINT LAURENT, QUEBEC--(Marketwire - December 04, 2009) - IntelGenx Technologies Corp. ("IntelGenx") (TSX VENTURE: IGX)(OTCBB: IGXT) announced today that the Company's board of directors granted options to acquire 125,000 common shares effective November 24, 2009. All options were granted under the 2006 Stock Option Plan with an exercise price of C$0.65 and expire in five years.

Of the total stock options grant, 25,000 were granted to each of the Company's non employee directors Bernard Boudreau, Ian Troup and Bernd Melchers and vest immediately. The company also granted 25,000 options to purchase common shares to each the CEO and President, Horst G. Zerbe and the CFO, Paul A. Simmons. The officer's options vest over the period of two years at the rate of 25 % every six months.

About IntelGenx Corp.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. Intelgenx's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis and depressive disorders. More information is available about the company at www.intelgenx.com.

The TSX Venture Exchange and OTC Bulletin Board have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.